Status:
COMPLETED
Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations
Lead Sponsor:
AstraZeneca
Conditions:
COPD
Eligibility:
All Genders
40+ years
Brief Summary
COPD patients frequently suffer intermittent exacerbations of their disease characterised by acute deterioration of symptoms. Acute exacerbations of COPD (AECOPD) are associated with significant impai...
Eligibility Criteria
Inclusion
- Signed informed consent
- Age ≥ 40 years
- Patients fulfilling criteria for COPD according to the Global initiative for chronic obstructive pulmonary disease (GOLD) stage I or higher
- Smokers or ex-smokers of at least 10 pack-years
- Patients suffering an AECOPD either:
- Admitted to hospital due to AECOPD (severe exacerbation) or
- Confirmed AECOPD at GP (general practitioner) setting (moderate exacerbation) Definition AECOPD: Increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both.
Exclusion
- Patients who have never smoked
- Patients with active long-term respiratory disease (e.g. bronchial asthma, cystic fibrosis, severe bronchiectasis, malignancy, restrictive lung diseases etc.)
- Exacerbation of COPD due to other causes such as pneumothorax and acute decompensated congestive heart failure
- Difficulties in communication (cognitive deterioration, sensorial disability, language barriers)
- Severe disease with poor vital prognosis (life length expectancy less than one year)
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
634 Patients enrolled
Trial Details
Trial ID
NCT01248507
Start Date
January 1 2011
End Date
April 1 2013
Last Update
October 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed Pharma S.A.
Madrid, Spain, 28023